New quality expertise at the heart of MB Therapeutics
As part of its expansion and commitment to ensuring the highest standards of pharmaceutical quality, MB Therapeutics is pleased to announce the integration of Manon Perez as responsible pharmacist and Chief Quality Officer (CQO).
Expertise in toxicology and pharmacovigilance
With a background in industrial pharmacy and a specialization in toxicology, risk assessment, and pharmacovigilance (Master THERV), Manon Perez has solid expertise in risk management, pharmacovigilance, and pharmaceutical quality systems.
Her experience has allowed her to gain a deep understanding of regulatory issues, risk management, and pharmaceutical quality requirements, particularly in strictly regulated environments such as Good Manufacturing Practices (GMP). Her experience and skills in quality management make her a key asset for MB Therapeutics.
A strategic role within MB Therapeutics
Joining MB Therapeutics is first and foremost joining an innovative company, driven by strong values and a clear ambition. It is an exciting challenge where quality excellence and regulatory rigor play a central role in ensuring patient safety.
MB Therapeutics continues to grow
With this new appointment, MB Therapeutics reaffirms its commitment to ensuring pharmaceutical inks that meet the most stringent requirements.
This development is part of a key phase in the company’s growth, marked by the opening of its new facilities and its pharmaceutical establishment dedicated to the production of pharmaceutical inks certified by GMP.
Manon Perez’s arrival in the quality management team further strengthens MB Therapeutics’ commitment to providing innovative, safe, and tailored solutions to patients.
